NASH and post-transplant metabolic syndrome
The presence or recurrence of metabolic syndrome following liver transplantation can contribute to the development and recurrence of NAFLD in the liver allograft...
NASH Observatory
⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
Read MoreNASH and post-transplant metabolic syndrome
Insulin resistance in MAFLD
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of NAFLD. This has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease...
NATIVE: first clinical trial demonstrating…
Treatment options for NASH are limited. S. M. Francque et al. (Antwerp University Hospital, Belgium) examined the effects of lanifibranor, a pan-agonist of the peroxisome proliferator–activated receptors with favourable effects on glucose and lipid metabolism, inflammation, and fibrosis, in 247 patients with active, noncirrhotic NASH...
Lanifibranor in NASH: NATiV3, an ongoing phase 3 trial
The New England Journal of Medicine has published the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH. Lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASH...
NASH and CV disease: new considerations
NASH is increasing with the current obesity pandemic. Prof. Robert Chilton (San Antonio - USA) reminds us that the current best practices to tackle the burden of this multi-system disease are currently lifestyle interventions
New insights into the role of inflammation in NAFLD
Dr. Moritz Peiseler (La Charité - Germany), discusses new scientific insights into the role of inflammation in NAFLD / NASH. He presents the spectrum of NAFLD and explains how inflammation can drive all the progressive stages of NAFLD. He also reviews hepatocellular carcinoma (HCC) risks and presents several studies and evolving treatments for NASH.
Outcomes in adults with NAFLD
Given the growing importance of NAFLD and its inflammatory manifestation, in a new prospective study from the NASH Clinical Research Network, A. J. Sanyal et al. describe outcomes for 1773 adults with biopsy-proven NAFLD with an average follow-up period of 4 years...
New targets for NAFLD
NAFLD is a growing cause of chronic liver disease worldwide. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD...
NAFLD and incident dementia in elderly patients
An association between NAFLD and brain aging has been suggested. Therefore, C. Labenz et al. aimed to investigate the hypothesis if NAFLD is an independent risk factor for emerging dementia...
Obese NAFLD children and adolescents: high BMI predicts liver fibrosis
H. Moran-Lev et al. (Dana Dwek Children’s Hospital, Tel Aviv University, Israel) aimed to investigate the predictors for liver fibrosis and the effects of short-term nutritional intervention on steatosis and fibrosis among obese adolescents with NAFLD...
NAFLD in the elderly
The diagnosis and management strategies of NAFLD in older adults are sometimes challenging, and certain age-specific factors have to be taken into account. In this review, S. A. Alqahtani (King Faisal Specialist Hospital & Research Center, Saudi Arabia and Johns...
NAFLD and incident chronic kidney disease
The association of NAFLD and CKD has been established before. The aim of this large-scale database study was to investigate the role of NAFLD on emerging CKD, the emergence of end-stage renal disease and the identification of additional risk factors which may increase the risk for CKD in Germany...